HLA
FATE icon

Hamilton Lane Advisors’s Fate Therapeutics FATE Stock Holding History

Hamilton Lane Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,350
Closed -$285K – 75
2022
Q1 		$285K Hold
7,350
– – 0.06% 64
2021
Q4 		$430K Sell
7,350
-7,553
-51% -$428K 0.06% 71
2021
Q3 		$883K Buy
+14,903
New +$1.17M 0.15% 55

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Hamilton Lane Advisors's FATE Position: Q2 2022 in Review

Hamilton Lane Advisors sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 7,350 shares — an estimated $285K sold.

Hamilton Lane Advisors first reported a position in FATE in Q3 2021 and held it in 3 quarters. The position peaked at $883K in Q3 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Hamilton Lane Advisors reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Hamilton Lane Advisors sold 7,350 Fate Therapeutics shares in Q2 2022, an estimated $285K.
  • Hamilton Lane Advisors first reported a position in Fate Therapeutics in Q3 2021 and held it in 3 quarters.
  • Hamilton Lane Advisors's Fate Therapeutics position peaked at $883K in Q3 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Hamilton Lane Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.